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Abstract
Recent molecular genetics studies have suggested various trans-synaptic processes for pathophysiologic mechanisms of
neuropsychiatric illnesses. Examination of pre- and post-synaptic scaffolds in the brains of patients would greatly aid further
investigation, yet such an approach in human postmortem tissue has yet to be tested. We have examined three methods
using density gradient based purification of synaptosomes followed by detergent extraction (Method 1) and the pH based
differential extraction of synaptic membranes (Methods 2 and 3). All three methods separated fractions from human
postmortem brains that were highly enriched in typical PSD proteins, almost to the exclusion of pre-synaptic proteins. We
examined these fractions using electron microscopy (EM) and verified the integrity of the synaptic membrane and PSD
fractions derived from human postmortem brain tissues. We analyzed protein composition of the PSD fractions using two
dimensional liquid chromatography tandem mass spectrometry (2D LC-MS/MS) and observed known PSD proteins by mass
spectrometry. Immunoprecipitation and immunoblot studies revealed that expected protein-protein interactions and
certain posttranscriptional modulations were maintained in PSD fractions. Our results demonstrate that PSD fractions can be
isolated from human postmortem brain tissues with a reasonable degree of integrity. This approach may foster novel
postmortem brain research paradigms in which the stoichiometry and protein composition of specific microdomains are
examined.
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specific receptor complexes, when combined with a proteomics
approach.
The PSD is a highly organized biochemical apparatus attached
to the postsynaptic membrane, which can be visualized as an
electron dense thickening under electron microscopy [20,21]. The
PSD contains glutamatergic receptors, N-methyl-D-aspartic acid
(NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor (AMPA), the group I metabotropic glutamate
receptors (mGluRs) and numerous signaling molecules [22,23].
As a molecular scaffold, the PSD brings together various sets of
signaling molecules and modulates their interactions and their
activities.
The PSD is relatively insoluble in non-ionic detergents and can
be purified by differential centrifugation [24,25]. Various
protocols have been used to isolate the PSD from rodent brains
based on a fundamental principle of: a) purification of synaptic
membranes, b) extraction of the membranes with non-ionic
detergents and c) separation of the resultant disk-shaped protein

Introduction
Recent studies in neuropsychiatric illnesses have implicated
various trans-synaptic mechanisms [1,2,3,4,5,6,7], for which
protein compositions in sub-cellular microdomains are crucial
[8,9,10,11,12]. The postsynaptic density (PSD) is a particularly
interesting microdomain since multiple candidate genes for
psychoses and mood disorders converge on its signaling mechanisms [5,6,7,13]. Thus, the ability to isolate the PSD, particularly
when combined with proteomic methods, will greatly aid our
understanding of neuropsychiatric illnesses. Indeed, such strategies
have been extensively utilized for the PSD derived from rodent
brains [14,15,16,17]. We, and others, have recently applied similar
approaches to human postmortem brains [18,19], but the
feasibility and validity have not been fully elucidated. In this
study, we evaluate a research paradigm to isolate biochemical
fractions enriched in the PSD of human postmortem brains, which
can then be used as a platform to profile the stoichiometry of
PLoS ONE | www.plosone.org
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structures. Protocols have often differed in the degree of detergent
extraction, thereby determining the inclusiveness of proteins in the
final fractions. These include Triton X-100 or N-lauryl sarcosinate
and the use of harsher detergents retrieves a more stripped down
version of proteins [24,25]. Indeed, variations of these methods
allowed separation of fractions containing synaptic vesicles and
synaptic membranes from the PSD [26,27].
Protein composition and stoichiometry of protein complexes
can be profiled using proteomic analysis. Several groups have
analyzed the rodent PSD using 2D fluorescence difference gel
electrophoresis (2D DIGE) or LC-MS/MS and identified sets of
proteins, including known PSD proteins previously characterized
by the immunoblot method [28,29,30,31]. However, depending
on the methods of fractionation and proteomics analysis, these
studies have reported variable numbers of proteins ranging from a
few hundred to more than a thousand. Posttranslational
modifications (PTM) appear to be maintained through the
rigorous biochemical fractionation procedure, and groups have
identified phosphorylation sites on PSD proteins [15,17,31,32].
These studies suggest that heavy isotope labeled synthetic peptides
could permit absolute quantification (AQUA) of peptides and
posttranslational modifications of proteins in this microdomain.
Biochemical fractionation of postmortem brain tissues faces
special challenges due to various confounding factors inherent to
these tissues [5,33]. They include prolonged agonal state,
complicating medical conditions, the post-mortem interval
(PMI), inconsistent pH, and duration of storage and temperature
of the tissues. These conditions are thought to disrupt the integrity
of proteins, ultrastructures or microdomains [34,35,36]. Therefore, few attempts have been made to isolate the PSD or other subcellular fractions from human postmortem brains [37]. In the
present study, we have isolated PSD fractions from human
postmortem brain tissues and verified the enrichment, protein
composition, and integrity of ultrastructures using Western blot,
electron microscopy and proteomic analysis. We propose this
approach as a new paradigm for postmortem brain study
permitting analysis of stoichiometry and protein-protein interactions in this microdomain.

To assess enrichment of the PSD, PSD fractions extracted by
Method 2 were analyzed compared to post-nuclear lysates
(referred to as synaptosomal fractions, SF) for the relative
quantities of PSD proteins compared to b-actin. Ratios of PSD95, NR1 and NR2B, with respect to b-actin levels, were
approximately 30 fold higher in PSD fractions than those in SF
(Fig 2B).
Three methods, as described in Fig 1A, were compared for the
yield and purity of fractions. From 500 mg of brain tissues,
Method 1 yielded 0.3 to 0.5 mg of SPM and 0.03–0.06 mg PSD,
Method 2 produced 1.4 mg SPM and 0.4 mg PSD and Method 3
yielded approximately 0.8 mg of SPM, 0.5 mg of SV, 0.25 mg of
PPF and 0.25 mg of PSD fractions. The purity of PSD fractions
was determined by the extent to which they contained presynaptic
protein and synaptic membrane bilayers. Ratios of synaptophysin
with respect to PSD-95 were compared between methods using
immunoblot analysis of fractions. The ratio of synaptophysin to
PSD-95 was lower in Method 1 than in Methods 2 or 3, indicating
that the purity of the fraction was superior in Method 1 by this
measure. As another measure of purity we quantified fragments of
synaptic membrane bilayers under EM. In eight randomly selected
EM fields (magnification 20,0006), 20% fewer synaptic membrane bilayers were observed in Method 1 than in Method 2.
Together, these indicate that the fraction purity was superior in
Method 1. PSD yield was unaffected by PMI, age or freezing time
of the brain tissues (Figure S1).

Stability of protein interactions and PTM
Postmortem confounds differ among subjects and can lead to
individual variability in the integrity of sub-cellular fractions
derived from the tissues. To test this possibility, we isolated PSD
fractions from the postmortem PFC of 12 subjects and compared
presynaptic and postsynaptic proteins. Age of the subjects varied
between 67 and 92 (7962.8). PMIs ranged from 3.5 to 22
(9.662.3) (Table 2), the 280uC storage time (after death) was from
5 to 17 years (10.261.9). Figure 2A shows that the pre-synaptic
molecules rab3 and synpatophysin were almost undetectable in all
PSD fractions, while PSD proteins, NR1, NR2A, erbB4, homer
and PSD-95 were highly enriched. The ratios of the intensity of
PSD-95 bands with respect to b-actin were calculated as a measure
of enrichment of PSD proteins. In PSD samples obtained from 12
subjects, the ratios of PSD-95/b-actin was 1.2460.08, of NR1/bactin was 1.7260.74 and of homer/b-actin was 0.7260.07.
Overall, the standard errors of these ratios were less than 15% of
the mean for each molecule.
Isolated PSD fractions can provide valuable information on
protein-protein interactions in the microdomain. To test whether
such molecular interactions are maintained during the rigorous
biochemical fractionation, we conducted an immunoprecipitation
(IP) experiment with PSD fractions obtained from 12 subjects
(Figure 2C). Those fractions were immunoprecipitated with
antibodies for NMDA receptor (NR1) and were probed for
PSD-95, phospholipase C (PLCc) and NR2A. Ratios of the
intensities of the bands for PSD-95 with respect to those for NR1
were 1.660.18 in SF fractions, and 1.060.09 for PSD fractions
(data not shown). Ratios of the intensities of the bands for PLCc
with respect to those for NR1 were 5.260.54 in SF fractions and
1.060.11 for PSD fractions (data not shown). The associations of
the proteins differ between SF and PSD fractions, yet the ratios of
SEM over means were overall comparable between the fractions,
suggesting that biologically significant interactions are still
maintained in the PSD fractions. Protein-protein interactions in
the PSD were unaffected by PMI age or freezing time of the tissue
samples (Figure S2).

Results
Protein enrichment in PSD fractions
Postmortem human PFC tissues were fractionated following the
protocols of Carlin et al [25] and Phillips et al [14,26], as well as by
combining these two methods with some modifications (named
Method 1, Method 2 and Method 3 respectively). All three
protocols first separated synaptic membrane fractions (SPM) using
a sucrose density gradient. In Method 1, the SPM was extracted
with Triton X-100 and then fractionated to the PSD with a second
sucrose density gradient (Figure 1A). In Methods 2 and 3, the SPM
was further fractionated by Triton X-100 extraction first at pH 6,
then at pH 8 (Figure 1A). The soluble fractions obtained after the
pH 6 and pH 8 Triton X-100 extractions were designated the
synaptic vesicular fraction (SV) and the presynaptic membrane
fraction (PPF), respectively. Insoluble fractions remaining after the
Triton X-100 extraction were defined as the PSD fraction.
All three methods produced fractions highly enriched in the
PSD from human postmortem brains. Figure 1B shows that PSD
proteins, NMDAR1, NMDAR2, Homer and PSD-95, were
enriched in the PSD fractions isolated by Method 1 (D9) or by
Method 3 (D), while these proteins are much less represented in
the fractions SV (V) or PPF (P). In contrast, presynaptic proteins,
Rab3, NRG1, synaptophysin, vGAT, vGlut1, were mostly
enriched in the SV fraction but not in the PSD fractions (D9 or D).
PLoS ONE | www.plosone.org
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Figure 1. The postsynaptic density (PSD) can be successfully isolated from human postmortem brains. (A) Diagram of fractionation
procedures. (B) Immunoblotting of fractions. Postmortem PFC tissues from two human subjects were fractionated by the procedure employing
sucrose density gradient and detergent extraction (Method 1) and by the procedure using pH based differential extraction of synaptic membranes
(Method 3). Various fractions from Method 3 and the PSD fraction from Method 1 were analyzed by immunoblotting. Abbrevations: T: total tissue
extracts, C: cytosolic extracts, S: SPM, synaptosomal membrane, V: SV, vesicular fraction, P: PPF: presynaptic fraction, D9: PSD isolated by the method 1, ’:
D:PSD isolated by the method 3. NR: NMDA receptor, Synph: synaptophysin, vGlut1: vesicular glutamate reuptake site.
doi:10.1371/journal.pone.0005251.g001

each depending on the purpose of projects. Methods 2 and 3 are
superior to Method 1 in the yield of PSD fractions and therefore
are more appropriate when the availability of the tissues is limited,
while Method 1 is recommended when the issue of purity is
critical.
EM examination of subcellular fractions showed relatively intact
ultrastructures in subcellular fractions from postmortem brains. In
SPM fractions, synaptosomes were well formed, containing intact
synaptic vesicles. In the PPF and much less frequently in the PSD,
scaffolds of opposing presynaptic and postsynaptic membranes
were observed, as shown in rodent counterparts [14,24,25]. In
addition, ultrastructural characteristics of PSD fractions appear
comparable to those previously reported in rodents [14,24,25].
These data support the notion that the PSD, as a microdomain, is
relatively well-maintained in postmortem brains, and can be
isolated to a reasonable degree of purity. Various confounding
factors associated with postmortem brain tissue may affect
subcellular ultrastructures and the integrity of proteins
[33,34,35]. These factors could contribute to variability in the
yield and protein composition of PSD fractions, which would
make comparisons between individuals or groups unreliable. A few
parameters that we have tested in the present study, however,
suggest that there is a reasonable degree of consistency in PSD
samples of human subjects. First, the rate of enrichment of PSD
proteins in the PSD fractions, tested in 12 subjects, appears to be
relatively consistent between samples (Figure 2a), while the PMI of
the subjects ranged between 3.5 and 22 h and the freezer storage
time varied from 5 to 17 years. Second, protein composition of the
PSD fractions, as assessed by the ratios of PSD-95 relative to NR1
for example, was grossly similar in the PSD fractions among all
subjects. The rate of enrichment and protein composition are
relatively consistent, most likely because the PSD is a resilient
microdomain that can endure harshness of the fractionation
procedures.
PSD fractions of postmortem brain tissue may permit the study
of protein-protein interactions with some confidence. The results
of the NR1 IP showed that the association of NR1 with PSD-95,
PLCc or NR2A in the PSD was almost as consistent among
individuals as those in the post-nuclear fractions (Figure 2C as an
example). This may suggest that the fractionation procedure of the
PSD does not disturb protein-protein interactions. It is of note,
however, that the association of NR1 with NR2A and PLCc was
lower in the PSD than in post-nuclear fractions (Figure 2C). This
could be due to different protein associations between the two
fractions. Alternatively, it may be the case that only more robust
protein-protein associations survive during the fractionation
procedure of the PSD, although the selective process is still
consistent among samples.
2D LC-MS/MS was employed to further characterize the
protein composition of PSD fractions. PSD enrichments from two
biological samples were combined in a statistical analysis, which
integrates data from consensual and non-consensual peptide
identifications in a Bayesian fashion (48). Our list of identified
proteins appears highly inclusive, yet provides an extensive
coverage of known PSD proteins, as evidenced by the proteins
cataloged in Table 1. Combined with Western blot results

EM analysis of fractions
The integrity of isolated fractions was tested using EM.
Figure 3A and B show a thin section electron micrograph of
SPM and demonstrate strikingly intact synaptsomes that contain
synaptic vesicles and filamentous connections to other synaptosomes. Figure 3C represents the soluble fraction of pH 6 Triton X100 extraction and shows paired pieces of electron dense
membranes. The more electron dense membrane is thought to
be postsynaptic. Figure 3D shows that the PSD fraction is largely
devoid of the fine substructures of synaptic junctions.

LC-MS/MS Data
Two biological samples of PSD fractions, enriched by Method
2, were analyzed by 2D LC-MS/MS. Peptide identifications were
assigned by SEQUEST (ThermoFisher) and peptide and protein
probabilities determined by Empirical Bayes Protein Identifier
(EBP) [38]. At a 1% false positive threshold 1863 nonredundant
proteins or protein groups were identified. A separate analysis
utilizing a reverse database yielded near identical protein
identifications at a 1% false positive cut off (data not shown).
Inspection of the identifications revealed proteins with welltheorized functions in the PSD, as identified by review of recent
literature [22,29], such as the Discs Large Homologs (IPI00552511,
IPI00647950 & IPI00790650), Homer (IPI00003566), SHANK
(IPI00019794), G proteins (e.g. IPI00290928), glutamate receptors
(e.g. IPI00297933), and various kinases (e.g. IPI00007128) and
phosphatases (e.g. IPI00008380). Peptides from 36 consensus PSD
proteins, as identified in Collins et al. [39], were selected and
confirmed by spectra inspection and/or targeted MS2 analysis of
peptide ions (Table 1). It is of note that many proteins unlikely to be
present in the PSD were evidenced, including pre-synaptic,
mitochondrial and translational proteins, indicative of the limitation
in selectivity of the applied separation method. The complete data
set can be viewed at Peptide Atlas, sample IDs 040804_HumanBrain and 052104_HumanBrain. For a complete list of proteins and
protein groups see: http://spreadsheets.google.com/pub?key =
pDgU17zRNrsAy-GrFicBkLQ

Discussion
The PSD contains molecular machineries for NMDA, AMPA
and mGlu receptors, all of which have been implicated in the
pathophysiology of various neuropsychiatric illnesses [40,41,42,43].
Thus, examining the PSD of patients’ brains will greatly aid
pathophysiologic investigations, yet such study paradigms have not
been developed for human postmortem brains.
The purpose of this study was to assess whether the PSD can be
isolated as a biochemical fraction from postmortem brains and to
test the integrity of these fractions. Our results show that methods
employing density gradient based purification (Method 1) [14,26]
and pH based differential extraction (Method 2, 3)[25], can
produce fractions that are highly enriched in the PSD proteins
with a reasonable degree of purity and in a reproducible fashion.
All three methods were effective in producing PSD fractions
that are mostly devoid of presynaptic proteins. A few differences
between these methods, however, may determine the utility of
PLoS ONE | www.plosone.org
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Figure 2. PSD protein composition and protein-protein interactions remain stable through fractionation. (A) PFC tissues from 12
subjects were processed using Method 3. PSD fractions were immunoblotted for postsynaptic and presynaptic molecules. (B) A representative
immunoblot for SF and PSD fractions from 2 subjects, fractionated by Method 2, that were probed for PSD proteins, PSD-95 and NR2B, and a
presynaptic protein, synaptophysin. b-actin was used as loading control. (C) SF and PSD fractions (Method 2) obtained from 4 subjects without
neuropsychiatric illnesses were immunoprecipitated for NMDAR1 and probed for NMDR2A and PLCc1 PSD-95, NMDAR1.
doi:10.1371/journal.pone.0005251.g002
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Figure 3. Electron micrographs of osmicated insoluble pellets obtained by Method 3). (A, B) Thin sections of SPM pellets show surprisingly
intact synaptosomes and intact synaptic vesicles (A, B) as well as filamentous crossbridges (see arrows in B). (C) Synaptic membrane fractions
extracted by Triton-X 100 at pH 6.0 show paired electron dense profiles representing synaptic junctions (see arrows in C). (D) PSD fraction obtained as
an insoluble phase after synaptic membranes were extracted with Triton-X 100 at pH 8.0. Note that presynaptic specialization is removed and that
the PSD is thinner than shown in A and B.
doi:10.1371/journal.pone.0005251.g003

Proteomic analyses are prone to detecting contaminants that are
either highly abundant in target tissues or co-enriched during
biochemical fractionation [22]. While our list of identified proteins
is highly inclusive, it may serve as a comprehensive list of proteins
in the PSD of human postmortem brains. The next step will be to
determine which of these proteins are specific to the PSD or highly
enriched in this microdomain. Once confirmed, PSD proteins on
the list can be quantitatively evaluated in conjunction with
immunoprecipitation and heavy label internal standards.

confirming enrichment of PSD proteins, our 2D LC-MSMS data
provide further evidence that PSD proteins can be enriched by a
biochemical fractionation of postmortem brain tissue. The number
of proteins in the PSD is presently unknown [22]. Using immunoEM, EM tomography, and scanning transmission EM, Chen et al
(2005) and Petersen et al (2003) have estimated that an average
PSD with a 360 nm diameter and a total molecular mass of
1.1060.36 gigadaltons, could be composed of 10,000 proteins of
100kD [44,45].

PLoS ONE | www.plosone.org
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Table 1. Peptides for consensus PSD proteins were observed in the PSD fractions of human postmortem brains.

%

Protein

IPI

Description

Cov

Probability

Accession

1

A-kinase anchor protein 5

18

1.00

IPI00307794

2

Brain Creatine Kinase

72

1.00

IPI00022977

3

Calmodulin

47

1.00

IPI00075248

4

CAMKII Alpha

43

1.00

IPI00877169

5

CAMKII Beta

40

1.00

IPI00334271

6

DLG1/SAP97/GKAP

7

1.00

IPI00552511

7

DLG2/PSD-93/Chapsyn-110

13

1.00

IPI00647950

8

DLG4/PSD-95

24

1.00

IPI00790650

9

Dynamin

59

1.00

IPI00887273

10

Glutamate receptor, ionotropic, AMPA 2

11

1.00

IPI00219216

11

Glutamate receptor, ionotropic, AMPA 3

9

1.00

IPI00298700

12

Glutamate receptor, ionotropic, NMDA 2A

3

1.00

IPI00029768

13

Glutamate receptor, ionotropic, NMDA 2B

6

1.00

IPI00297933

14

Glutamate receptor, metabotropic, 5

5

1.00

IPI00296244

15

Gai o

40

1.00

IPI00398700

16

Gai 2

27

0.97

IPI00748145

17

Gb 1

39

1.00

IPI00026268

18

Gb 2

47

1.00

IPI00003348

19

Gb 5

19

1.00

IPI00745232

20

Heat Shock Protein 70 12A

50

1.00

IPI00011932

21

Homer 1

21

1.00

IPI00003566

22

Inositol 1,4,5 Triphosphate receptor

5

1.00

IPI00333753

23

L-type calcium channel

10

1.00

IPI00219983

24

PKCa

28

1.00

IPI00385449

25

PKCc

27

1.00

IPI00007128

26

PKCe

20

1.00

IPI00024539

27

Protein phosphatase 1

23

1.00

IPI00045550

28

Protein phosphatase 2

20

1.00

IPI00000030

29

Protein tyrosine phosphatase, receptor type D

8

1.00

IPI00375547

30

Proto-oncogene tyrosine-protein kinase/Src

10

1.00

IPI00641230

31

Ras-related protein Rab-3A

12

1.00

IPI00023504

32

SH3 and multiple ankyrin repeat domains protein 3/SHANK3

14

1.00

IPI00847618

33

Rap guanine nucleotide exchange factor 2/Rap GEF2

12

1.00

IPI00853219

34

Ras GTPase-activating protein/SynGap

17

1.00

IPI00177884

35

R-type calcium channel

4

1.00

IPI00218338

36

Voltage-dependent anion-selective channel

21

1.00

IPI00216024

Peptide identifications were confirmed by inspection of MS2 spectra and targeted MS2 analysis of peptide parent masses. Description: IPI identifier. % Cov: Percent of
protein sequence covered by observed peptides. Peptides reported here have also been observed in at least three other analyses of mammalian PSD preparations as
described in Colins et al [39].
doi:10.1371/journal.pone.0005251.t001

cautions are exercised, however, this approach can provide
insights into protein-protein interactions that are critical for
glutamatergic and other signaling mechanisms in post-synaptic
neurons.

The ultimate goal of this study was to test a study paradigm in
which to examine the PSD of human postmortem brains with
respect to its integrity, protein composition, and protein
associations. Our results showed surprisingly well-maintained
ultrastructures in biochemical fractions, relatively consistent yield
of PSD fractions and the stability of protein compositions during
the fractionation procedure. Considering various postmortem
confounding variables and their effects on a wide array of
protein properties, it will still be important to be selective for
parameters that are stable enough for comparisons. When such
PLoS ONE | www.plosone.org

Materials and Methods
Subcellular fractionation of postmortem brain tissues
PSD fractionation Method 1. One gram of frozen human
postmortem brain tissue was homogenized in 5 ml of solution A and
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1.5 ml of solution A (0.1 mM CaCl2, 1 mM MgCl2 and 0.32 M
sucrose) supplemented with protease and phosphatase inhibitor
cocktails (Sigma). This homogenate was adjusted to 1.25 M
Sucrose and 0.1 mM CaCl2 to a total volume of 5 ml. 5 ml of
1 M sucrose was overlaid on this and ultracentrifuged at
28000 rpm (100,0006g) for 3 hrs in a SW 40 Ti rotor using a
Beckmann L7 Ultracentrifuge. The band at the interface of 1.25
and 1 was collected with a needle as SPM. The SPM was diluted
with 56 0.1 mM CaCl2 and centrifuged at 12000 rpm (150006g)
for 20 minutes. The pellet was solubilzed in 20 mM Tris pH 7.4
supplemented with protease and phosphatase inhibitors, and
sonicated with three 10 second pulses. Samples were added with a
combination of three detergents, 0.5% digitonin, 0.2% sodium
cholate and 0.5% NP-40 (final concentration), which would be
henceforth referred to as triple detergent, and the samples were left
for end over end shaking for 60 min in 4uC.
For PSD preparation, a 500 ml aliquot of SPM was diluted with ice
cold 0.1 mM CaCl2 to 2.5 ml, followed by the addition of 2.5 ml of
40 mM Tris-HCl pH 6 supplemented with 2% Triton-X 100 and
protease and phosphatase inhibitors, bringing the final volume to
5 ml with 20 mM Tris and 1% Triton-X 100. The samples were left
in cold room rocker for 30 minutes and centrifuged at 18000 rpm
(35,0006g) for 20 minutes. The supernatant, designated as the
vesicular fraction (SV), was then diluted with 56chilled acetone and
left in 220uC overnight. The pellet was air dried and dissolved in
1 ml CaCl2, then 1 ml 40 mM Tris pH 8 with 2% Triton-X 100 ,
was added for the final concentration of 20 mM Tris and 1% TritonX. The sample was left on a rocker for 60 minutes and centrifuged at
36000 rpm (140,0006g) for 30 minutes. The supernatant, designated
as the presynaptic membrane fraction (PPF) was acetone precipitated
at 220uC overnight. The pelleted PSD was air dried and dissolved in
20 mM Tris pH 7.4. Acetone precipitated SV and PPF fractions
were centrifuged at 15000 rpm (24,0006g) for 30 minutes and pellets
were dissolved in 500 ml of 20 mM Tris pH 7.4 with triple detergent.
PSD fractionation Method 3. One gm of postmortem brain
tissue was homogenized in 5 ml of solution A (0.32 M Sucrose,
1 mM NaHCO3, 1 mM MgCl2, 0.5 mM CaCl2 supplemented
with protease and phosphatase inhibitor mixtures), which was
labeled total homogenate (T). The sample was centrifuged at
2638 rpm (14006g) for 15 min at 4uC on Eppendorf 5810R, and
the supernatant was saved. The pellet was rehomogenized in 2 ml
of solution A, centrifuged at 1878 rpm (7106g) for 10 min, and
pooled with supernatants from the previous step. Pooled samples
were centrifuged at 13,800 rpm (160006g) in Eppendorf
Centrifuge 5415C, and the supernatant was saved as the
cytosolic fraction (C). The pellet was resuspended in 750 ml of
solution B (0.32 M sucrose, 1 mM NaHCO3 supplemented with
protease inhibitor mix and phosphotase inhibitors) and overlaid on
a three layer sucrose gradient that consisted of 3 mls of each
1.2 M, 1 M and 0.85 M sucrose. The gradient was spun for 2 hrs
at 28,000 rpm (100,0006g) in a SW40Ti rotor in a L7 Beckmann
ultracentrifuge. The band between 1.0 and 1.2 M sucrose
containing synaptosomes was removed, diluted with 56 solution
B and centrifuged for 30 minutes at 18000 rpm (35,0006g) in
Beckmann type 50Ti rotor. The interface at 1 M and 1.25 M
sucrose gradients was processed as described for the interface
between 1.2 and 1.0 M sucrose gradients. Protein concentrations
for SPM, SV, PPF and PSD fractions were determined by
Bradford’s method [46].

Table 2. Subject Information.

RX

Sex

Age

Race

PMI

Medication

N

F

74

W

3.5

no data

N

M

67

W

8

no data

N

F

74

W

6

no data

N

M

73

B

8

no data

N

M

86

W

7

no data

N

F

85

W

11

no data

N

F

80

W

15

no data

N

M

70

W

19

no data

N

F

89

B

7

no data

N

F

91

W

11.5

no data

N

F

72

W

7

Valcade

N

M

86

W

7

no data

N

F

83

B

22

no data

N

F

67

W

5.5

no data

N

F

92

W

5

no data

N

M

75

W

17

no data

S

F

75

W

9

Haloperidol

S

M

81

W

5

no medication

S

F

82

W

12

Clozapine

S

F

88

C

7.5

no medication

S

M

69

W

13.5

Prozac, Trazodone

S

F

76

W

9

no data

N: Normal, S: Schizophrenia, F: Female, M: Male, B: Black, W: White, C: Caucasian
doi:10.1371/journal.pone.0005251.t002

the samples were pelleted at 2638 rpm (14006g) for 15 minutes in
Eppendorf 5810R centrifuge. The pellet was re-homogenized in 2 ml
of solution A and centrifuged at 1878 rpm (7106g) for 10 minutes.
The supernatant was combined with supernatant from the previous
step, and centrifuged at 13,800 rpm (160006g) in Eppendorf
centrifuge 5415 C for 20 min. The pellet was resuspended in
750 ml of solution B and overlaid on a three-layer sucrose gradient
that consisted of 3 mls each of 1.2 M, 1 M, and 0.85 M sucrose. The
gradient was spun at 28,000 rpm (100,0006g) for 2 hrs in a SW 40
Ti rotor using a Beckmann L7 Ultracentrifuge. The band between 1
and 1.2 M interface was collected as SPM. 500 ml of the SPM was
diluted 56 with 0.1 mM CaCl2 and centrifuged at 12,000 rpm
(150006g) in Beckmann type 50 Ti rotor for 20 minutes. The pellet
was dissolved in 20 mM Tris pH 7.4, sonicated with three 10 second
pulses and solubilized in triple detergent as described above. The rest
of the SPM (,1.5 mls) was diluted with 0.1 mM CaCl2 to a total
volume of 7.5 mls, followed by the addition of 7.5 mls of 40 mM Tris
pH 8.0 with 2% Triton-X 100 to make a final volume of 15 mls
(20 mM Tris and 1% Triton-X) and left in cold room with end over
end shaking for 60 minutes. The samples were pelleted down at
40,000 rpm (172,0006g) in 50 Ti rotor and resuspended in 1 ml of
solution A. This resuspended pellet was overlaid on a three-layer
sucrose gradient made up of 3 mls each of 2, 1.5 and 1 M sucrose
and centrifuged at 44,000 rpm (200,0006g) in 50 Ti for 2 hrs. The
band between 2 and 1.5 M sucrose was collected as PSD. PSD
fractions were solubilized in triple detergent with sonication as
described above. Protein concentrations in SPM and PSD were
determined by Bradford’s method.
PSD fractionation Method 2. 300–350 mg of frozen
postmortem brain tissue was dissected and homogenized in
PLoS ONE | www.plosone.org

Synaptosomal fractions (SF)
100 mg of brain tissues was homogenized in 56 volume of
immunoprecipitation buffer (25 mM Tris HCl pH 7.4, 200 mM
NaCl, 2 mM EDTA, 0.5 mM EGTA and cocktails of protease
8

April 2009 | Volume 4 | Issue 4 | e5251

Human PSD Enrichment

and phosphatase inhibitors, (Sigma)). The samples were centrifuged at 3500 rpm (8006g) in Eppendorf 5415C for 15 min at
4uC. The supernatant was sonicated for 10 seconds on ice and
triple detergents were added. The samples were incubated at 4uC
for 60 min on an end over end shaker and were spun at
13800 rpm (110006g) for 10 minutes. The supernatant was
diluted with 0.75 mls of IP buffer and saved as synaptosomal
fraction (SF).

variation of the method described by Trinidad et al. [15]. Cysteine
side chains were reduced and alkylated by incubation with 5 mM
dithiothreitol (DTT) for 45 min at 60uC and 15 mM iodoacetamide
for 45 min at room temperature in the dark. The mixture was
diluted to a final concentration of 1 M guanidine with 25 mM
ammonium bicarbonate and 75 mg modified trypsin (Promega,
Madison, WI). The mixture was adjusted to a pH of 8.0 and
incubated for 12 hrs at 37uC. Digests were desalted with a Peptide
Macrotrap Cartridge (MICHROM Bioresources, Inc, Auburn, CA)
and lyophilized to ,5 ml. Peptides were re-suspended in 100 ml
strong cation exchange (SCX) buffer A (30% acetonitrile, 5 mM
KH2PO4, pH 2.7). SCX was performed on the entire sample using
an Agilent 1100 series HPLC with Chem Station for LC (Agilent
Technologies, Santa Clara, CA) using a PolySULFOETHYL
column, 2.1 mmID6100 mm, 5 m, 300 Å (The Nest Group,
Southborough, MA). SCX buffer B consisted of buffer A with
350 mM KCL. The gradient was held at 0% B for 9 min and then
went from 0% B to 29% B over 54 min, 29% B to 75% B over
45 min, and 75% B to 100% B over 9 min, with a flow rate of
100 ml/min. Fractions were collected every three minutes. The first
5 fractions were pooled, giving a total of ,50 fractions per sample.
Fractions were lyophilized and re-suspended in reverse phase (RP)
buffer A (0.5% acetonitrile 0.1% formic acid in H20). One tenth of
each individual SCX fractions was injected on a 5 ml loop from a
CTC pal auto-sampler (Leap technologies, Carrboro, NC) and
peptides loaded onto Vydac Everest C18 column, 300 Å, 5 mm,
100 mm, 500 mm ID (The Nest Group) at 20 ml/min in 100% RP
buffer A with an Express C100 system (Eksigent Technologies,
Dublin, CA). The mobile phase was diverted to waste for the first
10 min to remove KCl and other salts. The flow rate was then
reduced to 12 ml/min and peptides were eluted over a 50 min
gradient from 0% to 40% RP buffer B (5% H20, .1% formic acid in
acetonitrile). After elution the column was washed for 10 min with
100% RP buffer B and equilibrated for 10 min with 100% RP
buffer A. The LTQ mass spectrometer (ThermoFisher Scientific,
San Jose, CA) was operated in the positive ion mode using
electrospray ionization with a capillary temperature of 200uC.
Nitrogen was used as a sheath gas at 41 and an auxiliary gas at 12
(arbitrary units). MS spectra were acquired for a mass range of 400–
1200 m/z over 30 milliseconds. The top 5 most intense ions per
spectra were selected and sequenced with a collision induced
dissociation energy (CID) of 35.0 and an activation energy of 25
(arbitrary units). A dynamic exclusion window was applied to
prevent the selected ions from being sequenced for 200 ms after the
initial acquisition.

Electron Microscopy
Pellets were fixed in 2.5% glutaraldehyde/2% paraformaldehyde, embedded in epon, and post-stained with urayl acetate and
bismuth subnitrite. Ultrastructural examination was performed
with a JEOL JEM 21010 electron microscope. Images were
captured with a Hamamatsu CCD ORCA digital camera, using
AMT Advantage software version 5.4.2.308 (Advanced Microscopy Techniques).

Western blotting and Immunoprecipitation
To test enrichment of PSD proteins by Method 2, the T, C,
SPM (S), SV (V), PPF (P) and PSD (D), (also D9: the PSD
fractionated by Method 1) fraction protein extracts were separated
on 4–12% NuPage precast gel from Invitrogen (Figure 1B).
SF and PSD (fractionated by method 3) of the same human
subjects were compared by loading 30 mgs of SF and 5 mgs of PSD
protein extract in 7.5% SDS precast gels from Biorad (Figure 2B).
The samples were transferred on PVDF membrane (Millipore)
and probed with the following antibodies: mouse monoclonal PSD95, 1:1000 (Upstate or NeuroMab, UC Davis, CA), rabbit
polyclonal pS295-PSD-95 1:250 (Abcam), mouse monoclonal
synaptophysin 1:5000 (Chemicon), mouse monoclonal b-actin
1:5000 (Sigma), rabbit polyclonal ErbB4, goat polyclonal NR1,
goat polyclonal NR2A (Santa Cruz) , NR2B 1:1000 (a gift from Dr.
Barry Wolfe, Georgetown University Medical Center, Washington,
DC 20057, USA), rabbit polyclonal vGlut1 (Synaptic System),
mouse monoclonal Munc18 and RAB3 (BD Biosciences). The blots
were developed using chemiluminescent reagents ECL or ECLPlus, or a combination of both (GE Healthcare). 400 mgs of SF or
10 mg of PSD from the same subject were immunoprecipitated after
2 hours preclearing with Protein A agarose with 6 mg of goat
polyclonal NR1 antibody (Santa Cruz) in immunoprecipitation
buffer (25 mM Tris-HCl, pH 7.4, 200 mM NaCl, 2 mM EDTA,
0.5 mM EGTA supplemented with protease and phosphatase
inhibitors from Sigma) at 4uC overnight. The samples were
incubated with 25 ml of Protein A agarose Plus (Pierce) for 2 hrs
at RT. The immunoprecipitated samples were separated on a 7.5%
SDS precast gel (Biorad) and probed with mouse monoclonal PSD95, 1:1000 (NeuroMab), Goat Polyclonal NR1 and NR2A 1:500
and mouse monoclonal PLCc1 1:250 (Santa Cruz).

Analysis of LC-MS/MS Data
The data sets were searched against the International Protein
Index (IPI) human protein sequence database (version 3.43,
number of protein sequences: 72,346, total length of database
entries: 30,410,250 amino acid residues) for peptide sequences
using SEQUEST 3.1 (ThermoFisher, San Jose, CA). Raw mass
spectra were converted to DTA peak lists using BioWorks Browser
3.2 (ThermoFinnigan) with the following parameter settings:
peptide mass range 300–5000 Da, threshold 10, precursor mass
61.4 Da, group scan 1, minimum group count 1, minimum ion
count 15. SEQUEST searches specified that peptides should have
a maximum of two internal tryptic cleavage sites and possess two
tryptic termini, with methionine oxidation and cysteine carbamidomethylation as possible modifications and used a peptide mass
tolerance of 61.4 Da and a fragment ion tolerance of 0. The
search results were converted into pepXML format. Peptide
identification probabilities were calculated by executing PeptideProphet as implemented in the Trans-Proteomics Pipeline version

2D LC-MS/MS Analysis of Human PSD Enrichments
Tissue samples were dissected from the prefrontal cortex
(Brodmann area 9) of two healthy control human brain samples
in order to provide sufficient confidence in protein identifications.
The PSD was enriched by Method 2, for increased yield and
inclusiveness, and purity confirmed by western blot analysis of PDZ
domain and synaptophysin (Figure 1B). Each pellet was washed 3
times with 20 mM Tris pH 7.4 at 4uC and resuspended in 25 mM
ammonium bicarbonate with 6 M guanidine hydrochloride.
Protein concentration was determined by Coomassie Plus reagent
(Promega, Madison, WI) with a BSA standard curve read at 595 nm
on an EL808 Microplate Absorbance Reader (BioTek, Winooski,
VT. Two enrichments per biological sample were pooled to give
600 mg PSD protein. 2D LC-MS/MS was performed using a
PLoS ONE | www.plosone.org
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2.8 (Institute for Systems Biology, Seattle, WA) [47]. SEQUEST
results were processed using the ‘‘-Ol’’ tag, which uses DCn*
values unchanged.
Results from both biological replicates were combined in a
single statistical analysis of protein expression using the EBP 1.0 as
described previously [38]. Briefly, EBP estimates both sensitivity
and false identification rate and has been validated empirically for
LTQ ion trap data using a reversed/forward sequence database
search approach [38]. EBP combines the probabilities of correct
peptide identification across multiple peptide searches using a
function that returns the maximum probability from consensus
identifications, and penalizes non-consensual identifications.
Replicates are integrated by simultaneously estimating multiple
sets of model parameters. Peptides whose sequence matches
multiple proteins are integrated in the analysis using ‘‘Occam’s
Razor’’, a principle by which the smallest set of probable proteins
that is sufficient to explain the peptide sequence identifications is
chosen. When proteins cannot be reliably distinguished by unique
peptides, they are reported as a protein group. Only proteins with
expression probabilities corresponding to a false identification rate
of less than 0.01 (1%) were reported (1863 proteins). This was
equivalent to expression probabilities of p.0.90 in this data set.
One hundred thirty two additional proteins with p.0.90 were
members of groups of similar proteins, which could not be
distinguished based on the peptide evidence. A separate analysis
utilizing a forward/reversed database yielded near identical
protein identifications at a 1% false positive cut off (data not
shown).

Postmortem tissue collection consent and IRB
Consent for tissue collection was granted prospectively by
patients and autopsy consent granted by the next-of-kin at time of
death. The postmortem enrollment was conducted under Conte
Core A, IRB number 703835 and postmortem protocol was
conducted under IRB number 188200 of the University of
Pennsylvania.

Supporting Information
Figure S1 PSD yield is not affected by post mortem interval
(PMI), age or freezing time of the brain tissues. Yields of PSD
fractions isolated from 12 subjects free of any neuropsychiatric
illnesses were plotted against using Method 2. (A): Post mortem
Intervals (PMI) (B): Age and (C): Freezer time duration.
Found at: doi:10.1371/journal.pone.0005251.s001 (0.81 MB TIF)
Figure S2 Protein-Protein Interactions in PSD fractions are not

affected by post mortem interval (PMI), age or freezing time of the
brain tissues. Ratios of PSD-95/NR1 signals obtained from the
NMDAR1 immunoprecipitation of PSD extracts (fractionated by
Method 2) of 12 normal subjects free from neuropsychiatric
illnesses were plotted against: (A): Post mortem Intervals (PMI) (B):
Age and (C): Freezing time duration.
Found at: doi:10.1371/journal.pone.0005251.s002 (0.81 MB TIF)
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